Mersana Therapeutics, Inc.
MRSN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11,009 | $3,056 | $2,754 | $16,361 |
| % Growth | 260.2% | 11% | -83.2% | – |
| Cost of Goods Sold | $0 | $287 | $0 | $0 |
| Gross Profit | $11,009 | $2,769 | $2,754 | $16,361 |
| % Margin | 100% | 90.6% | 100% | 100% |
| R&D Expenses | $12,182 | $16,218 | $18,341 | $22,286 |
| G&A Expenses | $6,303 | $7,415 | $8,925 | $8,886 |
| SG&A Expenses | $6,303 | $7,415 | $8,925 | $8,886 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$287 | $0 | $0 |
| Operating Expenses | $18,485 | $23,346 | $27,266 | $31,172 |
| Operating Income | -$7,476 | -$20,577 | -$24,512 | -$14,811 |
| % Margin | -67.9% | -673.3% | -890.1% | -90.5% |
| Other Income/Exp. Net | -$69 | -$3,719 | $389 | $694 |
| Pre-Tax Income | -$7,545 | -$24,296 | -$24,123 | -$14,117 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,545 | -$24,296 | -$24,123 | -$14,117 |
| % Margin | -68.5% | -795% | -875.9% | -86.3% |
| EPS | -1.51 | -4.87 | -4.85 | -2.86 |
| % Growth | 69% | -0.4% | -69.6% | – |
| EPS Diluted | -1.51 | -4.87 | -4.85 | -2.86 |
| Weighted Avg Shares Out | 4,987 | 4,987 | 4,979 | 4,942 |
| Weighted Avg Shares Out Dil | 4,987 | 4,987 | 4,979 | 4,942 |
| Supplemental Information | – | – | – | – |
| Interest Income | $516 | $895 | $1,164 | $1,597 |
| Interest Expense | $394 | $674 | $775 | $903 |
| Depreciation & Amortization | $83 | $287 | $316 | $400 |
| EBITDA | -$7,068 | -$23,335 | -$23,032 | -$12,814 |
| % Margin | -64.2% | -763.6% | -836.3% | -78.3% |